Revolution Medicines’ daraxonrasib posted “landscape-changing” survival data at ASCO for metastatic pancreatic cancer driven by RAS G12 mutations, nearly doubling outcomes versus standard chemotherapy in its Phase 3 study. Across the trial population, daraxonrasib extended median survival to 13.2 months versus 6.6 months with chemotherapy for patients with RAS G12 mutations, and the all-comer comparison also separated more clearly than prior second-line benchmarks. Study investigators reported disease-control improvements alongside the survival signal, with median progression control rising in both the mutation-selected and broad trial cohorts. Separately, Revolution began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program. The company said the drug remains investigational, but demand accelerated after the April Phase 3 announcement. Together, the readout and early access step elevate daraxonrasib into the center of second-line RAS-mutant pancreatic cancer discussions and set up a near-term race to establish new treatment standards after years of limited options.